ABIVAX SA

Abivax SA’s anti‑viral pipeline—ABX 464 for HIV and ABX 203 for hepatitis B—showcases Paris‑based biotech’s global impact on infectious disease treatment and vaccine innovation.

Goldman Sachs spots hedge funds eyeing French biotech Abivax for its anti‑viral pipeline in emerging markets—investors see high‑growth potential beyond the U.S.

Abivax SA’s breakthrough antiviral therapies, from ABX 464 for HIV to ABX 203 for hepatitis B, showcase its global fight against viral diseases.

ABIVAX SA climbs Europe’s health sector rally, backed by strong earnings and a robust anti‑viral pipeline targeting HIV, hepatitis B, and more.

Abivax SA explores new acquisitions to boost its anti‑viral pipeline, sparking investor interest and potential stock gains.

Abivax’s $920 million capital raise lifts shares 7.7 % as it funds Obefazimod commercialization and expands its antiviral pipeline, sparking investor optimism.

Abivax SA’s €6.84 billion valuation surges after positive Phase‑III results for obefazimod (ABTECT), proving efficacy and safety for refractory ulcerative colitis and opening a new, lucrative UC market opportunity.

Abivax SA leads biotech with Phase II HIV cure trial ABX 464 and hepatitis B vaccine ABX 203, driving global infectious‑disease solutions and investor growth.

Abivax SA’s rising market sentiment stems from its growing anti‑viral pipeline and strategic collaborations, positioning it as a key player in global infectious disease therapeutics.

Abivax denies AstraZeneca takeover rumors, focusing on its pipeline of HIV, hepatitis B, and other infectious disease therapies.